Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea-Reference-Cited by-同舟云学术

Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea

Published:2019-06 Issue:6 Volume:41 Page:1066-1079
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Park Sun-Kyeong,Hong Sung-Hyun,Kim HyoJin,Kim Sungju,Lee Eui-Kyung

Funder

Novartis

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference58 articles.

1. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure;Yusuf;New Engl J Med,1991

3. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian enalapril survival study (CONSENSUS);CONSENSUS Trial Study Group;New Engl J Med,1987

4. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial;Granger;Lancet (London, England),2003

5. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial;McMurray;Lancet (London, England),2003

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Public value judgments about the criteria for reimbursement of medicines in South Korea;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-06

2. Cost–Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China;American Journal of Cardiovascular Drugs;2024-04-15

3. Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea;American Journal of Cardiovascular Drugs;2024-02-27

4. Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for Patients With Heart Failure in China;Journal of Cardiovascular Pharmacology;2024-01

5. Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review;Value in Health;2023-10